17
OAT AVENIN TRIGGERS ACUTE SYMPTOMS AND IMMUNE ACTIVATION IN SOME PEOPLE WITH CELIAC DISEASE BUT ADVERSE IMMUNE AND CLINICAL EFFECTS ARE ABSENT WITH EXTENDED INGESTION
Date
May 6, 2023
Explore related products in the following collection:
Tracks
Related Products
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
While the immunology of celiac disease is considered well understood, there have been a number of important developments in recent years which improve our understanding of disease triggers, symptom presentation and treatment challenges and may provide insights into other immune mediated diseases…